Xeris Pharmaceuticals XERS 深 沪
等待开盘 06-18 09:30:00 美东时间
6.90
0.000
0.00%
华盛通- 最 高7.055
- 今 开6.90
- 成交量 148.25万股
- 最 低 6.785
- 昨 收 6.90
- 总市值 11.91亿
- 52周最高 10.08
- 市盈率 静 2156.25
- 换手率 0.86%
- 52周最低 4.52
- 委 比 -94.41%
- 总股本 1.73亿
- 历史最高 27.983
- 量 比 0.70
- 振 幅 3.91%
- 历史最低 0.9701
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xeris Biopharma Announces Debt Reduction via Note Exchanges
Xeris Pharmaceuticals ( ($XERS) ) just unveiled an announcement. On June 10, 20...
06-11 19:45
Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Senior Notes Due 2028 To Retire ~$23M Of The Notes For ~$23M In Cash And A Number Of Shares
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements w...
06-11 19:09
Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $375.000M-$390.000M to $380.000M-$390.000M vs $383.864M Est
Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $375.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.864 million estimate.
05-07 19:11
Xeris Biopharma Announces Board Transition as Director Retires
Xeris Pharmaceuticals ( ($XERS) ) has issued an update. On April 20, 2026, Xeri...
04-22 04:58
Xeris Pharmaceuticals Earnings Call Highlights Rapid Growth
Xeris Pharmaceuticals (($XERS)) has held its Q4 earnings call. Read on for the ...
03-09 08:21
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Xeris Biopharma Holdings Q4 Earnings Assessment
The earnings results for Xeris Biopharma Holdings (NASDAQ:XERS) for Q4 were mad...
03-02 20:02
Xeris Biopharma Holdings Sees FY2026 Sales $375.000M-$390.000M vs $368.100M Est
Xeris Biopharma Holdings (NASDAQ:XERS) sees FY2026 sales of $375.000 million-$390.000 million vs $368.100 million analyst estimate.
03-02 20:01
Xeris Biopharma Holdings Q4 EPS $0.06 Beats $0.04 Estimate, Sales $85.807M Beat $82.340M Estimate
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 62.16 percent. This is a 300 percent increase over losses of $(0.03) per share
03-02 20:01
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
